Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient

Infection. 2019 Aug;47(4):665-668. doi: 10.1007/s15010-019-01319-0. Epub 2019 May 17.


Introduction: We describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation.

Hospital course: The patient developed multidrug resistant (MDR) Pseudomonas aeruginosa pneumonia, persistent respiratory failure, and colistin-induced renal failure. We describe the use of intravenous bacteriophage therapy (BT) along with systemic antibiotics in this patient, lack of adverse events, and clinical resolution of infection with this approach. She did not have recurrence of pseudomonal pneumonia and CF exacerbation within 100 days following the end of BT and underwent successful bilateral lung transplantation 9 months later.

Conclusion: Given the concern for MDR P. aeruginosa infections in CF patients, BT may offer a viable anti-infective adjunct to traditional antibiotic therapy.

Keywords: Antibiotic; Antimicrobial; Bacteriophage therapy; Cystic fibrosis; Lung transplant; Multidrug-resistant Pseudomonas aeruginosa.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cystic Fibrosis / complications
  • Drug Resistance, Multiple, Bacterial*
  • Female
  • Humans
  • Lung Transplantation
  • Phage Therapy*
  • Pseudomonas Infections / complications
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas aeruginosa / drug effects*
  • Treatment Outcome